LMR Partners’s Sarepta Therapeutics SRPT Stock Holding History

LMR Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31M	Sell	1,422,800 -30,000	-2%	-$581K	0.07%	151
2025 Q4	$31.3M	Buy	1,452,800 +70,500	+5%	+$1.49M	0.06%	145
2025 Q3	$26.6M	Buy	+1,382,300	New	+$24.6M	0.12%	140
2024 Q4	–	Sell	-87,700	Closed	-$11M	–	1576
2024 Q3	$11M	Sell	87,700 -58,400	-40%	-$8.07M	0.09%	204
2024 Q2	$23.1M	Buy	146,100 +11,700	+9%	+$1.5M	0.2%	102
2024 Q1	$17.4M	Sell	134,400 -100,600	-43%	-$12.3M	0.18%	117
2023 Q4	$22.7M	Sell	235,000 -132,200	-36%	-$12.7M	0.26%	92
2023 Q3	$44.5M	Buy	367,200 +28,200	+8%	+$3.19M	0.5%	39
2023 Q2	$38.8M	Buy	+339,000	New	+$43.7M	0.43%	55

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's SRPT Position: Q1 2026 in Review

LMR Partners reduced its Sarepta Therapeutics (SRPT) stake by 52% in Q1 2026, selling an estimated $300K and leaving 14,524 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

LMR Partners first reported a position in SRPT in Q2 2018 and has held it in 18 quarters since. The position peaked at $12.8M in Q2 2018. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

LMR Partners held 14,524 shares of Sarepta Therapeutics worth $316K as of Q1 2026.
LMR Partners sold 15,476 Sarepta Therapeutics shares in Q1 2026, an estimated $300K.
Sarepta Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1134 holding.
LMR Partners first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 18 quarters since.
LMR Partners's Sarepta Therapeutics position peaked at $12.8M in Q2 2018.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.